The Problem with Gluten

When gluten is consumed, the body’s pancreatic enzymes (pepsin, trypsin and chymotrypsin), which are found in the gastrointestinal tract, are unable to fully digest gluten proteins and some smaller undigested pieces of the gluten called ‘peptides’ remain.

Most people are not affected by these peptides. For others with recognised gluten disorders, these undigested peptides interact with intestinal lining, causing a cascade of events that leads to symptoms, inflammation and the associated autoimmune response that leads to intestinal damage.

An Innovative Natural Enzyme

When taken before a meal, GluteGuard’s enteric coating ensures its quick delivery to the small intestine where the enzymes are released. The enzymes target and breakdown the peptides into harmless fragments, which then follow through the normal digestive process without causing symptoms or immune activation.

Scientifically Supported

GluteGuard was extensively researched in-vitro and in randomised placebo controlled clinical trials exploring the effect of caricain supplementation on symptoms and biomarkers of gluten related conditions. These trials demonstrated that GluteGuard was successful at protecting participants against the effects of a daily gluten challenge^.

In other words, our research has shown that GluteGuard works in the real world for real people.

Based on decades of scientific research

GluteGuard is the culmination of decades of Australian clinical and scientific research. Early work by Prof. Hugh Cornell illustrating the biochemical composition of gluten, has been instrumental to today’s understanding of gluten’s toxicity in gluten related disorders.

Prof. Hugh Cornell OAM, a former Professor of Biological Chemistry at the RMIT University and Dr. Teodor Stelmasiak a veterinary pathologist with over 25 years of experience in pharmaceutical research, hypothesised that if the right enzyme is delivered to the gastrointestinal tract prior to the consumption of foods, it could complete the digestion of the toxic and immunogenic gluten peptides ultimately protecting patients against the effects caused by inadvertent gluten ingestion.

This was followed by the discovery of Caricain, which became the catalyst for the establishment of Glutagen by Dr Stelmasiak in 2001 and the subsequent development of GluteGuard.

GluteGuard was extensively researched in-vitro and in randomised placebo controlled clinical trials exploring the effect of caricain supplementation on symptoms and biomarkers of gluten related conditions. These trials demonstrated that GluteGuard was successful at protecting participants against the effects of a daily gluten challenge^.

For healthcare professionals enquiring about GluteGuard’s clinical research please visit:

GluteGuard’s Healthcare Professional’s website

^Cornell JH et al. 2016 IJCD Vol. 4, No: 2 p:40-47
Zebrowska A et al. 2014 – IJCD Vol 2, No 2 p:58-63.
These clinical studies were funded by Glutagen Pty Ltd.